BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» 4SC Stock Plummets on Vidofludimus Miss in RA
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
4SC Stock Plummets on Vidofludimus Miss in RA
June 9, 2011
By
Cormac Sheridan
No Comments
Shares in 4SC AG dropped 36 percent Wednesday on news that its orally available drug vidofludimus missed the primary endpoint of a Phase IIb clinical trial in rheumatoid arthritis, dashing investor hopes of a near-term deal.
BioWorld